ArticleCurrent medical science2026
Invasiveness, SOX2 Expression, and Resection Outcomes in TF-Defined PitNETs After Extra-Pseudocapsular Resection.
Article in Current medical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectiveTo evaluate the associations between transcription factor (TF)-defined molecular lineages and the clinical characteristics of pituitary neuroendocrine tumors (PitNETs).
methodsA retrospective cohort analysis was performed in 274 patients who underwent extra-pseudocapsular transsphenoidal resection. Tumors were classified by TF-defined lineage and invasion grade (0-3) and Knosp score. Group differences were tested, and predictors of gross total resection (GTR) were examined using hierarchical multivariable logistic regression.
resultsTF-defined lineage classification improved diagnostic precision. Among tumors with an immunonegative hormone profile, 74.7% received a definitive lineage assignment. The pituitary transcription factor 1-growth hormone/prolactin (PIT1-GH/PRL) subgroup had the highest incidence and grade of invasion; SRY-box transcription factor 2 (SOX2) positivity was most frequent in this subgroup (41.7%), which also exhibited the lowest GTR rate (58.3%). SOX2-positive tumors were associated with significantly higher preoperative adrenocorticotropic hormone (ACTH) (median: 38.80 vs. 31.60 pg/mL, P = 0.032) and GH (median: 1.12 vs. 0.43 ng/mL, P = 0.046) levels. SOX2 positivity was 20.5% in multilineage tumors and 20.0% in the recurrent cohort (n = 20). Compared with Trouillas grade alone, the combination of invasion grade and intraoperative features (capsule status and vascularity) significantly improved the ability to predict GTR (AUC, 0.866 vs. 0.795; ΔAUC = 0.071; DeLong 95% CI, 0.022-0.120; P = 0.005).
conclusionsThe 2022 WHO TF-defined lineage system improves diagnostic precision and facilitates the interpretation of PitNET differentiation and molecular pathology. Tumors in the PIT1-GH/PRL subgroup demonstrate more aggressive invasive features. SOX2 positivity was relatively frequent in multilineage tumors, whereas the observation in recurrent cases was limited by the small exploratory cohort and requires validation in larger longitudinal studies.
Indexed as
Identifiers
42545569What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.